ASARM Peptide Inhibits Vascular Calcification in CKD-MBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic kidney disease-mineralization bone disorder (CKD-MBD) and associated conditions like calciphylaxis and nephrogenic systemic fibrosis are inadequate in managing hyperphosphatemia and preventing vascular calcification, leading to significant morbidity and mortality.
Innovation Solution
Administration of the ASARM peptide, which inhibits phosphate uptake, binds to nanocrystals, and prevents the transition of vascular smooth muscle cells to osteoprogenitor cells, thereby reducing mineralization and calcification in tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If phosphate binders or dietary modification are used to reduce inorganic phosphate levels, then hyperphosphatemia is treated, but the progression of vascular calcification and extra-skeletal mineralization continues
Solution Approach 1:
The patent introduces ASARM peptide as an intermediary substance that specifically binds to calcium phosphate nanocrystals and calciprotein particles. This mediator prevents these phosphorus-containing structures from depositing in vascular tissues, thereby addressing vascular calcification while managing hyperphosphatemia through a targeted mechanism rather than general phosphate reduction
Solution Approach 2:
The patent converts the harmful effect of phosphorus-containing nanocrystals and calciprotein particles (which cause vascular calcification) into a beneficial therapeutic approach by using ASARM peptide to bind these particles and redirect them toward renal excretion. The same phosphorus structures that cause harm are now controlled and eliminated through a regulated pathway
2Reliability
If conventional treatments are used for CKD-MBD, then some symptoms are managed, but mortality and morbidity remain significant due to abnormal bone remodeling and extra-skeletal calcification
Solution Approach 1:
The ASARM peptide acts as a mediator that specifically targets and binds to calcium phosphate nanocrystals and calciprotein particles, preventing their deposition in extra-skeletal tissues and abnormal bone remodeling. This intermediary approach addresses the root cause of harmful mineralization rather than merely managing symptoms
Solution Approach 2:
The patent segments the treatment approach by specifically targeting different phosphorus-containing structures (nanocrystals and calciprotein particles) with the ASARM peptide, allowing selective inhibition of pathological mineralization processes while preserving normal physiological functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASARM peptide effectively corrects hyperphosphatemia, reduces tissue calcification, and improves survival in CKD-MBD patients by inhibiting mineralization and calcification processes, thereby addressing the progression of CKD-MBD and associated disorders.
Implementation Method 1
binds to nanocrystals
Implementation Method 2
inhibits phosphate uptake
Data Source
AI summary
A method of treating or inhibiting a kidney disorder can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for the kidney disorder (treat disease) and/or inhibit development of the kidney disorder (prophylactic). The kidney disorder can be selected from the group consisting of chronic kidney disease mineral bone disorder (CKD-MBD), calciphylaxis, nephrogenic systemic fibrosis (NSF), end stage renal disease, and combinations thereof. The therapy can include inhibiting vascular calcification (VC), hard tissue calcification, soft tissue calcification, mineralization, or combinations thereof in the subject with the ASARM peptide. A method of inhibiting mineralization can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for inhibit mineralization in the subject. A method of treating hyperphosphatemia can include administering a therapeutically effective amount of the ASARM peptide to a subject to provide a treatment for hyperphosphatemia.